Biotechnology firm Akadeum Life Sciences announced the closing of a $20 million financing round that will enable the company to advance its CGT product suite.
Michigan Capital Network led the investment alongside contributions from Arboretum Ventures, NYBC Ventures, and other investors. The funding follows the launch of the firm’s GMP-compliant product launch and will be used to scale commercial operations and support customers entering clinical trials.
Akadeum specializes in a buoyancy-based cell separation technology. Company partners include a number of high-profile biotechnology firms, including Catalent, Lonza, Charles River Laboratories, and ElevateBio. The company also won the Technology Disruptor of the Year Award for its microbubble cell separation platform during January 2025’s Advanced Therapies Week in Dallas, Texas. READ MORE